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ABSTRACT: According to present estimations, the un-
favorable combination of alleles with low penetrance but
high prevalence in the population might account for the
major part of hereditary breast cancer risk. Deleted in
Malignant Brain Tumors 1 (DMBT1) has been proposed
as a tumor suppressor for breast cancer and other cancer
types. Genomewide mapping in mice further identified
Dmbt1 as a potential modulator of breast cancer risk.
Here, we report the association of two frequent and linked
single-nucleotide polymorphisms (SNPs) with increased
breast cancer risk in women above the age of 60 years:
DMBT1 c.–93C4T, rs2981745, located in the DMBT1
promoter; and DMBT1 c.124A4C, p.Thr42Pro,
rs11523871(odds ratio [OR] 5 1.66, 95% confidence
interval [CI] 5 1.21–2.29, P 5 0.0017; and OR 5 1.66;
95% CI 5 1.21–2.28, P 5 0.0016, respectively), based on
1,195 BRCA1/2 mutation-negative German breast cancer
families and 1,466 unrelated German controls. Promoter
studies in breast cancer cells demonstrate that the risk-
increasing DMBT1 –93T allele displays significantly
decreased promoter activity compared to the DMBT1
–93C allele, resulting in a loss of promoter activity. The
data suggest that DMBT1 polymorphisms in the 50-region
are associated with increased breast cancer risk. In
accordance with previous results, these data link
decreased DMBT1 levels to breast cancer risk.
Hum Mutat 31:60–66, 2010. & 2009 Wiley-Liss, Inc.
KEY WORDS: DMBT1 gene; DMBT1 polymorphisms;
breast cancer risk; risk factor
Introduction
Breast cancer is the most common cause of cancer-related death
in women and, after lung cancer, the second most frequent cancer
worldwide [Parkin et al., 2005]. Familial breast cancer accounts
for approximately 5 to 10% of all breast cancers [Balmain et al.,
2003; Nathanson et al., 2001; Wooster and Weber, 2003]. Germline
mutations in BRCA1/2 occur in about 20 to 30% of all familial
breast cancer cases and in 2 to 3% of all breast cancers [Balmain
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et al., 2003; Meindl, 2002; Wooster and Weber, 2003]. According
to the polygenic model of inherited breast cancer, unfavorable
combinations of genetic variants in low-penetrance susceptibility
genes jointly contribute to the excess familial breast cancer risk.
However, most of these susceptibility genes have not been
discovered yet [Pharoah et al., 2002].
The gene Deleted in Malignant Brain Tumors 1 (DMBT1; GenBank
NM_004406.2), located on human chromosome 10q26.13, encodes
for a secreted high-molecular-weight glycoprotein of the scavenger
receptor cysteine-rich (SRCR) superfamily [Mollenhauer et al.,
1997]. The protein is expressed predominantly by epithelial cells.
Lumenally secreted variants have been shown to play a role in the
defense against bacterial and viral infections as well as in the
regulation of inflammatory responses [Bikker et al., 2002; Hartshorn
et al., 2003; Prakobphol et al., 2000; Rosenstiel et al., 2007]. In
contrast, secretion of the protein to the extracellular matrix (ECM)
may trigger processes of epithelial and/or stem cell differentiation
[Takito and Al-Awqati, 2004; Vijayakumar et al., 1999].
Mutations within DMBT1 have been found only infrequently
across various cancer types. The major mode of inactivation seems
to be a downregulation at the transcriptional level, which, in some
cancer types, is probably preceded by an upregulation during early
tumorigenesis. In fact, various infectious, inflammatory, and
carcinogenic stimuli lead to upregulation of DMBT1 in vitro and
in vivo, suggesting its role in early protective responses [reviewed in
Ligtenberg et al., 2007; Mollenhauer et al., 2007]. This may be
particularly important in the mammary gland epithelium, where an
early upregulation of Dmbt1 protein has been observed after
treatment of mice with the breast cancer–inducing carcinogen 7,12-
dimethybenz(a)anthracene (DMBA), while human breast cancer
cells frequently display a downregulation compared to the flanking
normal breast epithelium [Braidotti et al., 2004; Mollenhauer et al.,
2004]. Recent genomewide mapping in Trp531/ mouse strains
with differential breast cancer susceptibility depending on the
genetic background have recovered a 25-Mb region at mouse
chromosome 7 designated as the Suppressor of mammary tumors 1
(SuprMam1) locus [Blackburn et al., 2007]. This locus also includes
the mouse Dmbt1 gene. Expression profiling has identified Dmbt1
as 1 out of only 3 genes, which have displayed decreased expression
levels in the normal mammary gland epithelium of the breast
cancer susceptible vs. the resistant mice. Immunohistochemical
studies further have suggested lower DMBT1 levels in the normal
mammary gland epithelium of women with breast cancer compared
to women without it [Blackburn et al., 2007].
Based on these data, we hypothesized that DMBT1 could
represent a candidate for a novel breast cancer susceptibility gene.
To test this hypothesis, we analyzed two single-nucleotide
polymorphisms (SNPs), which are part of a larger haplotype block
in the 50-region of DMBT1, for their association with breast cancer
risk in a large collection of index cases of 1,195 breast cancer families
lacking BRCA1/2 mutations and 1,466 healthy control individuals.
Materials and Methods
Study Population
Genomic DNA was extracted from the peripheral lymphocytes.
All breast cancer cases were classified into six categories: (A1)
families with two or more cases of breast cancer including at least
two cases with onset under the age of 50 years; (A2) families with
at least one male breast cancer case; (B) families with one or more
cases of breast and at least one ovarian cancer; (C) families with
two or more cases of breast cancer including one case diagnosed
before the age of 50 years; (D) families with two or more cases of
breast cancer diagnosed after the age of 50 years; or (E) a single
case of breast cancer with diagnosis before the age of 35 years.
Thus, we accumulated familial cases and cases with early onset,
which are more likely to be due to a genetic cause, in our study
population. The breast cancer cases comprised only unrelated
women that had been tested BRCA1/2 mutation-negative by
applying the denaturing high-performance liquid chromatography
(DHPLC) method on all exons, followed by direct sequencing of
conspicuous exons. The samples, all of Caucasian origin, were
collected during the years 1997 to 2005 by six centers of the
German Consortium for Hereditary Breast and Ovarian Cancer
(GC-HBOC: centers in Heidelberg, Würzburg, Cologne, Kiel,
Düsseldorf, and Munich, see author affiliations for names). Index
patients were first diagnosed with breast cancer and then referred
to a family registry. All breast cancer patients gave an informed
consent. The control population included healthy and unrelated
female blood donors collected by the Institute of Transfusion
Medicine and Immunology (Mannheim, Germany), sharing the
ethnic background and sex with the breast cancer patients. The age
distribution in the controls and cases was nearly identical
(controls: mean age 45.6 years, median age 46 years; cases: mean
age 45.1 years, median age 45 years). According to the German
guidelines for blood donation, all blood donors were examined by
a standard questionnaire and gave their informed consent. They
were randomly selected during the years 2004 to 2007 for this
study and no further inclusion criteria were applied during
recruitment. The study was approved by the Ethics Committee of
the University of Heidelberg (Heidelberg, Germany).
Choosing blood donator controls might have resulted in a
selection bias. However, the selection factors are unlikely to be related
to the SNPs of interest. Furthermore, established susceptibility loci
have shown the expected associations/odds ratios (ORs) in the GC-
HBOC study population [Ahmed et al., 2009; Dunning et al., 2009;
Frank et al., 2005; Milne et al., 2009; Shephard et al., 2009].
Genotyping
Genotyping analyses were performed on whole-genome-ampli-
fied (WGA) DNA of BRCA1/2 mutation-negative index patients
from 1,195 German breast cancer families and 1,466 unrelated
German controls. The whole genome amplification (WGA) of
original genomic DNA was performed with the GenomiPhi DNA
amplification kit (GE Healthcare Life Sciences, Piscataway, NJ)
according to Wong et al. [2004] and the F29 DNA polymerase as
described by Paez et al. [2004], respectively.
The polymorphisms DMBT1 c.–93C4T; rs2981745 and
DMBT1 c.124A4C, p.Thr42Pro; rs11523871 were investigated
using TaqMan allelic discrimination. Primer and TaqMan MGB
probes were purchased from Applied Biosystems (Foster City,
CA): DMBT1c.–93C4T: forward 50-TTAGCAAAAGCCCTCACTT-
CCTT-30, reverse 50-GGTGTGTCCTCTAGGGTGGTA-30; Taq-
Man probes: forward 50-CAGCAGCAGAAATA-30-VIC, reverse
50-CAGCAGTAGAAATA-30-FAM; DMBT1c.124A4C: forward 50-
CCATCAATGAGCTCTTCCTTTTCCA-30, reverse 50-TCCCCCA-
TAATAGACCTTACCTTCTG-30; TaqMan probes: forward
50-CCCTTGGATACAACTGT-30-VIC, reverse 50-CCTTGGATCC-
AACTGT-30-FAM. Five nanograms of genomic DNA were used
per assay. PCR was carried out at 501C for 2 minutes; 951C for
10 minutes; and 40 to 45 times at 921C for 15 seconds and 601C
for 60 seconds. Samples were analyzed with the ABI Prism
7900 HT detection system using SDS 1.2 software (Applied
                                    61
Biosystems). The polymorphisms were named relative to the
reference sequence NM_004406.2 with nucleotide positions
given for the cDNA, numbered with 11 corresponding to A
of the start codon, ATG, in accordance with the recommendations
of the Nomenclature Working Group [Antonarakis, 1998]
(www.hgvs.org/mutnomen).
Statistical Analysis
Hardy-Weinberg equilibrium (HWE) test was undertaken using
the chi-square ‘‘goodness-of-fit’’ test. Genotype-specific ORs, 95%
confidence intervals (CIs), and P-values were computed by
unconditional logistic regression using a tool offered by the
Institute of Human Genetics, Technical University Munich,
Munich, Germany (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). P-values
were calculated using two-sided chi-square test. Given our sample
size, we calculated a power of 80% (a5 0.05) to detect an OR of
1.25. Given our sample size, we had a power of 80% (a5 0.05) to
detect an OR of 1.25 for both SNPs using the power and sample
size calculation software PS version 2.1.31 (www.mc.vanderbilt.
edu/prevmed/ps/index.htm), not considering the inclusion of
familial cases. The power of an association study based on familial
cases is about two times higher compared to a study of unselected
cases [Antoniou and Easton, 2003]. Pairwise linkage disequili-
brium (LD) was calculated between the investigated SNPs among
the control population using |D0| and r2 based on the Haploview
program by Mark Daly [Barrett et al., 2005] (www.broad.mit.edu/
mpg/haploview/documentation.php) and the HapMap project
(http://hapmart.hapmap.org/BioMart/martview/JIUfVsn0GF.mart).
The LD between the SNPs was evaluated with the Haploview
software [Barrett et al., 2005].
Cell Lines and DMBT1 Expression Analyses
Cell lines MCF7, T47D, MDA-MB-231, MCF10A, MCF12A,
and BT549 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). T47D and BT549 cells were
cultivated in RPMI 1640 medium with 1 mg/ml insulin; MCF10A
and MCF12A cells were cultivated in Dulbecco’s modified Eagle’s
medium (DMEM) F12 with 10 mg/ml insulin, 0.5 mg/ml hydro-
cortisone, and 20 ng/ml human epidermal growth factor (hEGF);
MCF7 cells in DMEM with 10 mg/ml insulin; and MDA-MB-231
cells in DMEM. All cell lines were cultured with 10% fetal calf
serum (FCS) (except for MCF10A and MCF12A with 5% FCS),
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin, at 371C in a humidified, 5% CO2 environment. Cells
grown to 80% confluency were used for RNA extraction. Total
RNA was isolated using the RNeasy kit from Qiagen (Hilden,
Germany), according to the manufacturer’s protocol. The RNA
(500 ng total RNA) was then reversely transcribed into cDNA
using oligo-dT priming. For quantitative reverse transcription
PCR (qRT-PCR) we used 10 ng cDNA and a TaqMan assay on-
demand (Hs01069306_m1) for the DMBT1 gene (Applied
Biosystems) according to the supplier’s instructions. All TaqMan
reactions were done in triplicate and signal detection was
performed by a 7300 Real-Time PCR system (Applied Biosys-
tems). The cycle thresholds (Ct) were normalized against the Ct
values obtained for the human housekeeping genes b-actin and
GAPDH. The DDCt value was calculated based on the DCt values
of the control. The expression level was than calculated as XL
(expression level) 5 2 – DDCt. Analyses were made by the SDS
v1.2 program and the RT-PCR program Biogazelle (free download
at www.biogazelle.com).
Analysis of Promoter Activities
A 1,029-bp product comprising the activator region of the DMBT1
promoter [Lualdi et al., 2000] was amplified by PCR from genomic
DNA of a donor heterozygous for the DMBT1 c.–93C4T SNP using
the primers DMBT1/1278 (50-GCG AGC TCA GCC TCT CAG CTG-
AGA AGC AG-30) and DMBT1/1241 (50-CTG TGG AGA TCC CCA-
TGG TGC TGG GTT CTT C-30). A 446-bp SacI/NcoI (50-part;
Fig. 1A) restriction fragment was inserted into the SacI/NcoI-digested
pGL3B vector. Subsequently, the 562-bp NcoI (30-part) restriction
fragment containing either the DMBT1 –93C or the DMBT1 –93T
variant was cloned into the NcoI-digested pGL3B vector already
containing the 50-part. Finally, we excised the 683-bp NdeI/BsrGI
fragment from the construct with the DMBT1 –93Tallele and inserted
it in the NdeI/BsrGI digested vector with the DMBT1 –93C allele. This
yielded constructs with the firefly luciferase reporter gene under
control of the activator region of the DMBT1 promoter, which were
identical except for the DMBT1 c.–93C4T. Of each plasmid or of the
empty pGL3B vector (control without promoter) 480 ng were
transiently cotransfected with 20 ng of Renilla luciferase-encoding
vector into MDA-MB-231 breast cancer cells (1 105 cells in 24-well
format) using the GeneJammer transfection reagent (Stratagene,
La Jolla, CA). We used the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) and a LUMIstar Omega luminometer
(BMG LABTECH, Offenburg, Germany) for detection of reporter
and transfection control gene expression 30 hours posttransfection as
recommended by the suppliers. We calculated firefly:Renilla luciferase
activity to adjust for transfection efficacy. The values were normalized
against background activity of empty vector controls. Two indepen-
dent experiments were performed in triplicate transfections, and data
were compared by the two-tailed Student’s t-test.
Results
We performed a case–control study analyzing BRCA1/2 mutation-
negative female index patients from 1,195 breast cancer families and
1,466 female unrelated German controls. Previous studies indicated
that decreased DMBT1 mRNA and/or protein expression levels in the
mouse and human mammary gland epithelium could potentially be
associated with breast cancer susceptibility [Blackburn et al., 2007].
We thus selected for initial analyses two SNPs in the 50-region of the
DMBT1 gene, which are part of a larger haplotype block. This
comprised a C/T polymorphism at position –93 bp in relation to the
DMBT1 start codon (rs2981745; DMBT1 c.–93C4T) and a second
closely linked SNP (rs11523871; DMBT1 c.124A4C, p.Thr42Pro;
r2 5 0.93, D 5 0.98). DMBT1 c.–93C4T is located between two
putative alternative transcription initiation sites [Mollenhauer et al.,
1997], while the coding SNP is located within a domain of unknown
function subsequent to the putative signal peptide and resulted in a
nonconservative amino acid exchange (p.Thr42Pro), which was
predicted to have possible functional consequences according to the
in silico prediction programs SIFT (http://blocks.fhcrc.org/sift) and
PolyPhen (http://coot.embl.de/PolyPhen).
Genotype distribution in cases and controls were consistent
with the HWE for both SNPs. As quality control 5% of the
samples for each study were randomly selected and subjected
to repeated analysis, yielding a concordance rate of 100%.
Genotyping call rates for all studies were higher than 98%.
Logistic regression analyses of DMBT1 c.–93C4T; rs2981745
revealed a significant association of the homozygous –93T
genotype with familial breast cancer (OR 5 1.37, 95% CI 5
1.04–1.80, P 5 0.022; Table 1). Similarly, homozygous carriers of
the C allele of DMBT1 124C (42Pro) were found significantly
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more frequent among breast cancer cases than among controls
(OR 5 1.34, 95% CI 5 1.02–1.75, P 5 0.035; Table 1). Age
adjustment did not have appreciable effects on the respective
ORs (OR 5 1.35 for DMBT1 c.–93C4T and OR 5 1.31 for
DMBT1 c.124A4C, comparing rare homozygous genotype
carriers vs. frequent homozygous genotypes). Both SNPs occurred
with considerable frequencies in the control group (0.288 for
DMBT1 –93T allele and 0.298 for DMBT1 124C allele).
To analyze whether the breast cancer risk associated with these
polymorphisms potentially varied in different age groups, we
divided the breast cancer cases and controls into five age groups:
r30 years, 430 to r40 years, 440 to r50 years, 450 to r60
years, and 460 years; and calculated the OR between cases and
controls of the respective age group. Interestingly, only the age
group including breast cancer cases and controls 460 years of age
showed a significant association of the –93T allele with an
increased breast cancer risk (OR 5 1.66, 95% CI 5 1.21–2.29,
P 5 0.0017; Table 1). The risk effect was stronger for homozygous
–93T variant allele carriers (OR 5 3.54, 95% CI 5 1.71–7.34,
P 5 0.00039; Table 1). In addition, the C allele of the DMBT1
124C (42Pro) was found significantly more frequently in cases
than in controls in the Z60 age group (OR 5 1.66, 95%
CI 5 1.21–2.28, P 5 0.0016; Table 1). Similar to the finding for
the –93T allele, the risk was increased in homozygous carriers of
the 124C allele (OR 5 3.23, 95% CI 5 1.55–6.72, P 5 0.0011;
Table 1). The w2-test for trend showed an allele dose-dependent
association of the respective minor allele with increased familial
breast cancer for both the DMBT1 c.–93C4T; rs2981745 and the
DMBT1 c.124A4C, p.Thr42Pro; rs11523871, respectively
(Ptrend 5 0.00157 and Ptrend 5 0.00129; Table 1).
The status of the breast tumors for the estrogen receptor (ER)
and the progesterone receptor (PR) was available for a subset of
the cases (305 cases ER1/PR1 and 308 cases ER–/PR–).
Stratification according to this parameter did not recover
statistical significant differences in odds ratios between the
hormone receptor positive and negative status (data not shown).
The two SNPs are part of a larger haplotype block, containing at
least two further exonic SNPs, located further three-primed in
codon 52 and codon 54. Furthermore, within the first 1 kb of the
DMBT1 promoter immediately preceding the start codon and
previously shown to harbor activating elements [Lualdi et al., 2000;
Rosenstiel et al., 2007], there is—except for the DMBT1 c.–93C4T
SNP—another eight SNPs, a dinucleotide and tetranucleotide
insertion/deletion polymorphism (not shown). The coding SNPs
locate in an amino acid motif of so far unknown function and
previous studies indicated that lower DMBT1 expression levels
could be associated with increased risk for breast cancer in mice
and humans [Blackburn et al., 2007]. Of the various SNPs in the
DMBT1 promoter, the DMBT1 c.–93C4T SNP was of particular
interest, because it represented the only alteration within the first
270 bp preceding the start codon and further located between two
putative transcription initiation sites (Fig. 1A) [Mollenhauer et al.,
1997]. We thus cloned the 1 kb promoter fragment in front of a
firefly luciferase reporter gene with either a C or a T at position
93 bp (Fig. 1A). Quantitative RT-PCR analyses suggested that
MDA-MB-231 breast cancer cells display appreciable DMBT1
mRNA expression levels (Fig. 1B), which were thus selected for
studying promoter activities. The data suggested that the breast
cancer associated DMBT1 93T variant displayed no significant
promoter activity compared to the promoter-deficient control
vector (10%77%; P 5 0.14 according to the Student’s two-tailed
t-test; not shown), while the DMBT1 –93C variant displayed
significantly higher promoter activity (P 5 8 108 compared to
the empty vector, and P 5 0.0005 compared to the DMBT1 –93T
variant; Fig. 1C). These data suggested that the DMBT1 –93T
variant, which is associated with an increased risk for breast cancer,
displays a strongly reduced promoter activity in vitro.
Discussion
Low penetrance susceptibility genes are considered to contribute
a major portion of hereditary breast cancer risk due to the common
occurrence of risk variants within the population [Pharoah et al.,
Figure 1. Comparison of the promoter activities of the DMBT1
c.–93C4T variants. A: (Top line) schematic presentation of the 1 kb
promoter region with relevant recognition sites for restriction
enzymes. According to previous data, this region contains elements
that activate DMBT1 transcription [Lualdi et al., 2000; Rosenstiel et al.,
2007]. (Bottom line) magnification of the region containing the DMBT1
c.–93C4T. The SNP locates between two presumable alternative
transcription initiation sites (TS1 and TS2), located at positions –106
and –73 bp in relation to the ATG start codon [Mollenhauer et al.,
1997]. B: Determination of relative DMBT1 expression levels in normal
breast and breast cancer cell lines by qRT-PCR. The values were
referred to MCF7 cells (set as 1). The breast cancer cell line MDA-
MB-231 displayed highest expression levels. According to the Ct value
of 25 for DMBT1 (and a DCt value of 3.7 compared to b-actin), it
represented the only cell line with substantial expression levels.
C: Relative reporter gene (firefly luciferase) activity in MDA-MB-231
cells of the 1 kb promoter fragment with either the DMBT1 –93T or the
DMBT1 –93C polymorphism. The variant with the DMBT1 –93C
polymorphism displays significantly higher activity compared to the
one with the DMBT1 –93T polymorphism (P 5 0.0005 according to
the two-tailed Student’s t-test). Error bars represent standard error of
the mean (SEM).
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2002]. Initial studies of breast carcinogenesis in human tumors and
mouse models pointed to a role for DMBT1 as tumor suppressor
and/or susceptibility gene for breast cancer [Blackburn et al., 2007;
Braidotti et al., 2004; Mollenhauer et al., 2004].
Our genetic studies assessed the relevance to familial breast
cancer of the two linked DMBT1 variants DMBT1 c.–93C4T;
rs2981745 and DMBT1 c.124A4C, p.Thr42Pro; rs11523871.
A recent study reported that SNPs located close to the estrogen-
and progesterone-responsive elements (EREs and PREs) within the
DMBT1 promoter are not associated with risk for sporadic breast
cancer but may affect survival of breast cancer patients [Lei et al.,
2007]. Using a Cox regression analysis to evaluate the combined
effect of genotype grade, PR and ER status on survival, the authors
observed a two-fold increased risk for the rare AA genotype when
compared with that for CC (RR 5 2.0, 95% CI 5 1.0–5.0, P 5 0.04),
suggesting a worse survival for the AA genotype carriers than the
CC genotype carriers, independent of grade and hormone receptor
status [Lei et al., 2007]. Because HapMap data are not available for
these SNPs, we could not perform an analysis to determine their
linkage disequilibrium to the SNPs analyzed in the present study.
We found that homozygous carriers of the DMBT1 –93T and
DMBT1 124C (42Pro) variant were significantly overrepresented in
the breast cancer group. The risk effect was stronger in the group
including breast cancer cases and controls 460 years old. The
strength of the present study is the large sample size of familial
index cases resulting in high statistical power. Furthermore,
exclusively BRCA1/2 mutation negative familial breast cancer cases
were included in the study to avoid the effects deriving from
mutations in these high-penetrance susceptibility genes.
We wanted to compare our data with results of the Cancer
Genetic Markers of Susceptibility (CGEMs) study database, an
National Cancer Institute (NCI) enterprise initiative to conduct
Whole Genome Association Studies (WGAS) to identify genes
giving rise to prostate and breast cancer risk by analyzing about
1,140 breast cancer cases and 1,140 controls via Illumina
HumanHap550 assays (U.S. female nurses; https://caintegrator.
nci.nih.gov/cgems). However, neither both SNPs themselves, nor
SNPs with r2Z0.80 have been analyzed in CGEMs.
Previous data indicated that decreased DMBT1 mRNA and
protein levels in the mouse and human mammary gland
epithelium, respectively, could be associated with increased breast
cancer risk [Blackburn et al., 2007]. In the present study, we
therefore focused on the 50-region of the gene, which presumably
contains critical elements for the regulation of DMBT1 mRNA
expression [Lualdi et al., 2000; Rosenstiel et al., 2007] and
processing of the protein, e.g., the signal peptide [Mollenhauer
et al., 1997]. The promoter polymorphism is located 146 bp
downstream from 1 of the 6 progesterone receptor (PR) binding
sites occurring in the 50 flanking region of DMBT1 [Ace and
Okulicz, 2005] and 21 bp upstream of the TATA-Box (www.cbil.
upenn.edu/tess). Further, it locates between two putative alter-
native transcription initiation sites (Fig. 1A) [Mollenhauer et al.,
1997] and represents the only polymorphism in the 270 bp
preceding the ATG start codon. According to our promoter
studies in vitro, the single substitution of the C for a T at position
93 results in virtually abolishing the promoter activity of the
1 kb activatory region of the DMBT1 promoter. This is in good
agreement with earlier findings suggesting that lowered DMBT1
expression levels confer susceptibility to breast carcinogenesis
[Blackburn et al., 2007], and with the present observation that the
DMBT1 –93T variant increases breast cancer risk.
The DMBT1 c.–93C4T variant is in very high LD (D 5 0.98,
r2 5 0.93) with DMBT1 c.124A4C, p.Thr42Pro, resulting in a
nonsynonymous threonine to proline exchange. Furthermore, the
first 1 kb of the DMBT1 promoter contains another eight SNPs
and two insertion/deletion polymorphisms, predicting that the
DMBT1 –93T variant occurs in cis with a number of further
Table 1. Genotype Frequencies of DMBT1 Polymorphisms
93C4T and Thr42Pro in All and in Different Age Groups in the
German Study Population
SNP Genotypes Cases Controls OR 95% CI P
All cases and controls
CC (%) 585 (49.1) 740 (50.5) 1
CT (%) 481 (40.3) 609 (41.5) 0.99 0.85–1.17 0.991
TT (%) 127 (10.6) 117 (8.0) 1.37 1.04–1.80 0.022
[T] 2 [C] 1.10 0.98–1.24 0.103
Cases and controls r30 years
CC (%) 40 (51.3) 143 (45.8) 1
CT (%) 31 (39.7) 143 (45.8) 0.77 0.46–1.21 0.339
TT (%) 7 (9.0) 26 (8.4) 0.96 0.39–2.38 0.934
[T] 2 [C] 0.89 0.61–1.31 0.561
Cases and controls 430 to r40 years
CC (%) 126 (46.8) 105 (45.8) 1
– 93C4T CT (%) 116 (43.1) 106 (46.3) 0.91 0.63–1.32 0.625
rs2981745 TT (%) 27 (10.1) 18 (7.9) 1.25 0.65–2.39 0.501
[T] 2 [C] 1.03 0.78–1.34 0.840
Cases and controls 440 to r50 years
CC (%) 83 (43.9) 244 (51.0) 1
CT (%) 88 (46.6) 183 (38.3) 0.71 0.49–1.01 0.056
TT (%) 18 (9.5) 51 (10.7) 0.96 0.53–1.74 0.903
[T] 2 [C] 0.87 0.67–1.12 0.285
Cases and controls 450 to r60 years
CC (%) 112 (56.0) 223 (57.2) 1
CT (%) 88 (44.0) 131 (33.6) 1.34 0.94–1.90 0.106
TT (%) 20 (10.0) 36 (9.2) 1.11 0.61–1.99 0.738
[T] 2 [C] 1.17 0.89–1.51 0.247
Cases and controls 460 years
CC (%) 47 (41.6) 186 (53.8) 1
CT (%) 49 (43.4) 141 (40.7) 1.37 0.87–2.17 0.170
TT (%) 17 (15.0) 19 (5.5) 3.54 1.71–7.34 0.00039
[T] 2 [C] 1.66 1.21–2.29 0.0017
Ptrend 5 0.00157
All cases and controls
AA (%) 569 (47.6) 714 (48.7) 1
AC (%) 497 (41.6) 631 (43.1) 0.99 0.84–1.16 0.886
CC (%) 129 (10.8) 121 (8.2) 1.34 1.02–1.75 0.035
[C] 2 [A] 1.08 0.97–1.22 0.153
Cases and controls r30 years
AA (%) 42 (51.2) 141 (45.1) 1
AC (%) 33 (40.2) 145 (46.3) 0.76 0.46–1.27 0.302
CC (%) 7 (8.6) 27 (8.6) 0.87 0.35–2.14 0.762
[C] 2 [A] 0.86 0.59–1.26 0.441
Cases and controls 430 to r40 years
Thr42Pro AA (%) 121 (45.3) 99 (43.8) 1
124 A4Ca AC (%) 117 (43.8) 107 (47.3) 0.89 0.62–1.30 0.559
rs11523871 CC (%) 29 (10.9) 20 (8.9) 1.19 0.63–2.22 0.594
[C] 2 [A] 1.01 0.77–1.32 0.934
Cases and controls 440 to r50 years
AA (%) 240 (49.9) 81 (42.9) 1
AC (%) 190 (39.5) 91 (48.1) 0.70 0.49–1.00 0.052
CC (%) 51 (10.6) 17 (9.0) 1.01 0.55–1.85 0.968
[C] 2 [A] 0.88 0.68–1.14 0.334
Cases and controls 450 to r60 years
AA (%) 110 (50.5) 215 (54.9) 1
AC (%) 87 (39.9) 141 (35.9) 1.21 0.85–1.72 0.297
CC (%) 21 (9.6) 36 (9.2) 1.14 0.63–2.05 0.660
[C] 2 [A] 1.13 0.87–1.46 0.367
Cases and controls 460 years
AA (%) 42 (37.5) 178 (51.4) 1
AC (%) 54 (48.2) 147 (42.5) 1.56 0.98–2.46 0.057
CC (%) 16 (14.3) 21 (6.1) 3.23 1.55–6.72 0.0011
[C] 2 [A] 1.66 1.21–2.28 0.0016
Ptrend 5 0.00129
Including ORs with 95% CIs, and P-values. Bold indicates significant values.
aRelative to ATG according to NM_004406.2.
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genetic variations. Thus, it should be taken into consideration that
other polymorphisms might exist that affect the DMBT1
promoter activity, including elements located outside the 1 kb
segment analyzed in the present study that might modulate
mRNA expression, translation or posttranslational processing.
Hence, systematic studies of the single and combined effects of
these variations would be necessary. Furthermore, it has to be
considered that larger deletion/insertion polymorphisms were
detected in the DMBT1 gene. These substantially alter the number
of SRCR domains within the protein, which are thought to exert
critical functions in ligand interactions [Bikker et al., 2002;
Mollenhauer et al., 2002; Renner et al., 2007]. The corresponding
exons reside within a repetitive region located 30 to the SNPs
analyzed in the present study, and may consist of up to 13
repeats sharing high homology in exon and intron sequences
[Mollenhauer et al., 1997, 1999, 2002]. Probably due to high
recombination rates, these deletion/insertion polymorphisms are
in poor LD to the SNPs in the flanking regions [Mollenhauer
et al., 1999; Renner et al., 2007]. Accordingly, the association
observed for the SNPs in the present study could also indicate an
involvement of the deletion/insertion polymorphisms.
Taken together, we identified DMBT1 as a candidate for a novel
low-penetrance breast cancer susceptibility gene, in particular for
the age group of women of 460 years. The precise mechanistic
background remains to be determined, but the fact that the breast
cancer risk-increasing DMBT1 –93T promoter polymorphism
significantly decreases the activity of the promoter in vitro is in
good agreement with earlier data suggesting that low DMBT1
levels might be associated with an increased breast cancer risk in
mice and humans.
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